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Summary
 
The pleiotropic cytokine interleukin 4 (IL-4) has been shown to regulate many processes
thought to be important in the allergic diathesis. To determine the mechanism(s) by which IL-4
mediates allergic airway responses to inhaled allergens, we compared the effects of antigen sen-
sitization and challenge on the development of allergic airway responses in mice in which the
gene for the signal transducer and activator of transcription factor 6 (Stat6) was disrupted to
those of their wild-type littermates. Strikingly, Stat6-deficient mice failed to develop airway
hyperresponsiveness (AHR), which was observed in their wild-type littermates after allergen
provocation. Moreover, antigen-induced increases in mucus-containing cells were found to be
completely Stat6 dependent. Consistent with the lack of Th2 cytokine responses in Stat6-defi-
cient mice, no ovalbumin-specific immunoglobulin (Ig)E was detected in their serum. In con-
trast, Stat6 signaling only partially mediated antigen-induced eosinophilia with no role in vas-
cular adhesion molecule 1 expression. These results indicate that Stat6 signal transduction is
critical in the development of allergen-induced AHR and that agents that specifically inhibit
this pathway may provide a novel strategy for the treatment of allergic disorders.
 
A
 
llergic asthma is characterized by airway hyperrespon-
siveness to specific and/or nonspecific stimuli, chronic
pulmonary eosinophilia, elevated serum IgE levels, and ex-
cessive mucus production. The pathology associated with
asthma is thought to be mediated by CD4
 
1
 
 T lymphocytes
producing the type 2 cytokines, IL-4 and IL-5, as both
messenger RNA and protein levels of these cytokines are
elevated in bronchial biopsies (1), bronchoalveolar lavage
(BAL)
 
1
 
 cells (2, 3), and blood (3) of allergic patients as
compared to normal individuals. Since these cytokines pro-
mote the accumulation and activation of eosinophils (4, 5)
as well as IgE synthesis by B cells (6), this cytokine pattern
has been thought to be important in the pathogenesis of
asthma. Although considerable circumstantial evidence ex-
ists for this hypothesis in human asthma, the use of animal
models of allergic inflammation has allowed more in-depth
examination of the importance of Th2 cytokines in the
pathogenesis of allergic inflammation. We have previously
demonstrated that in fact the development of airway hyper-
responsiveness (AHR) and pulmonary eosinophilia after al-
lergen provocation is CD4
 
1
 
 T cell dependent (7). Consis-
tent with studies in allergic asthmatics, the allergic phenotype
in murine models has been associated with elevations in
lung messenger RNA and protein levels of the type 2 cy-
tokines, IL-4 and IL-5 (8, 9). Of the Th2 cytokines, IL-4
in particular has been shown to be essential in the patho-
genesis of allergen-induced AHR. Specifically, AHR, eosin-
ophilic inflammation, and IgE production normally seen af-
ter local antigen challenge do not develop in mice in which
the gene for IL-4 is disrupted (10) or in animals in which
the cytokine (11) or its receptor (9) are blocked in vivo. In
addition, recent studies demonstrate that IL-4 may also be
important in the production of mucus by the airway epi-
thelium (9). Despite substantial evidence for the impor-
tance of IL-4 in allergic asthma, it has been difficult to as-
certain the specific mechanisms by which it mediates the
pathogenesis of allergic disease because of its plethora of ac-
tions. IL-4 has been shown to be the primary determinant
of differentiation of CD4
 
1
 
 T cells into Th2 cytokine–pro-
ducing cells (12). In addition to its pivotal role in CD4
 
1
 
 T
 
1
 
 
 
Abbreviations used in this paper:
 
 Ach, acetylcholine chloride; AHR, airway
hyperresponsiveness; BAL, bronchoalveolar lavage; IRS, insulin receptor
substrate; PDGF, platelet-derived growth factor; Stat6, signal transducer
and activator of transcription factor 6; VCAM-1, vascular cell adhesion
molecule 1.
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cell differentiation, IL-4 also exerts many biological actions
that may be important in the pathogenesis of allergic
asthma such as its role in B cell production of IgE (6), up-
regulation of vascular cell adhesion molecule 1 (VCAM-1)
on vascular endothelial cells (13), and its role in mastocyto-
sis (14). Studies in murine models have suggested that IL-
4’s primary role is in commitment of CD4
 
1
 
 T cells to the
Th2 cytokine–producing phenotype and that subsequent
IL-5 production may be the important factor (15); how-
ever, other studies demonstrate that IL-4 mediates antigen-
induced AHR independently of IL-5 and eosinophils (16).
The pleiotropic actions of IL-4 are mediated via a cell
surface receptor composed of a cytokine-specific 
 
a
 
 chain
and the common 
 
g
 
c chain used by several other cytokines
(17). Recent studies also demonstrate that the 
 
a
 
 chain of
the IL-4 receptor is a component of the high affinity IL-13
receptor (17). Ligation of the IL-4 receptor results in the
activation of at least two distinct signaling pathways. One
involves the activation of signal transducer and activator of
transcription factor 6 (Stat6) through phosphorylation by
Januse kinase (JAK)1 and JAK3 (18, 19). Once activated, Stat6
proteins form homodimers, translocate to the nucleus, and
directly bind to specific promoter sequences to regulate gene
transcription. In addition to Stat6 activation, stimulation of
the IL-4 receptor has also been shown to induce the phosphor-
ylation of an insulin receptor substrate (IRS) termed IRS-2
(20, 21). Activated IRS-2 associates with phosphatidylino-
sitol 3-kinase and may be responsible for certain IL-4–induced
responses such as proliferation in response to IL-4. Previous
studies in Stat6-deficient (Stat
 
2
 
/
 
2
 
) mice have suggested that
despite the multiple signaling pathways activated by IL-4,
Stat6 signaling is essential for mediating most responses of
lymphocytes to IL-4 (22–24). Specifically it has been
shown that Stat6-deficient animals are unable to generate
Th2s or undergo class switching to IgE production. In con-
trast to its role in mediating responses of lymphocytes to
IL-4, the role of Stat6 signaling pathways in other IL-4–
mediated processes is virtually unknown.
The goal of this study was to gain further insight into the
mechanisms by which IL-4 mediates the development of
allergen-induced AHR. To this end, we compared the ef-
fects of allergen exposure on the development of allergen-
induced AHR, pulmonary eosinophilia, BAL cytokine levels,
immunoglobulin production, and mucus cell numbers in
Stat6-deficient mice and their wild-type littermates (Stat
 
1
 
/
 
1
 
).
Our results demonstrate that Stat6 signaling is essential in
the production of Th2 cytokines in response to antigen
challenge and in subsequent development of allergen-induced
AHR. However, Stat6 signaling only partially mediates an-
tigen-induced eosinophilia with no role in VCAM-1 ex-
pression. These results suggest that agents that specifically
inhibit this pathway may be useful therapeutically for the
modulation of chronic inflammation in allergic disorders.
 
Materials and Methods
 
Mice.
 
Male and female Stat6-deficient and wild-type mice
backcrossed six generations onto a BALB/c background were
generated and bred at Harvard School of Public Health (Boston,
MA) as previously described (22). Animals were housed under
laminar flow hoods in an environmentally controlled pathogen-
free animal facility for the duration of experiments. They were
given free access to tap water and OVA-free rodent chow. The
studies reported here conformed to the principles for laboratory
animal research outlined by the animal Welfare Act and the De-
partment of Health, Education and Welfare (National Institutes of
Health) guidelines for the experimental use of animals (
 
n
 
 
 
5
 
 4–9
mice/experimental group, 9–12 wk of age).
 
Antigen Sensitization and Challenge.
 
Stat6-deficient and wild-
type mice were sensitized by intraperitoneal injection of 10 
 
m
 
g
OVA (crude grade IV; Sigma Chemical Co., St. Louis, MO) in
0.2 M PBS/ALUM (Sigma Chemical Co.) or PBS/ALUM alone
twice, 1 wk apart. 1 wk after the last sensitization, mice were
anesthetized with a mixture of ketamine and xylazine (45 and 8
mg/kg, respectively) and challenged by aspiration with 50 
 
m
 
l of a
1.5% solution of OVA or an equivalent volume of PBS. The ef-
fect of Stat6 deficiency on airway responsiveness, pulmonary in-
flammation, cytokine expression, and immunoglobulin synthesis
was compared in wild-type and Stat6-deficient mice either sensi-
tized and challenged with PBS (i.e., PBS treated) or OVA (i.e.,
OVA treated). 3 d after aspiration challenge, airway responsive-
ness to intravenous acetylcholine chloride (Ach) administration
was determined, the number of inflammatory cells and cytokine
levels in BAL fluid was determined, lungs were fixed in 10% for-
malin (Lyne Laboratories, Stoughton, MA), and blood was col-
lected for analysis of serum immunoglobulin levels.
 
Airway Responsiveness Measurements.
 
Airway responsiveness to
intravenous Ach challenge was measured as previously described
(8, 10). In brief, mice were anesthetized with sodium pentobar-
bital (90 mg/kg) and intubated with a 20-gauge tracheal cannula
equipped with a port for airway pressure measurements. Mice
were ventilated at a rate of 120 breaths/min with a constant tidal
volume of air (0.2 ml). A laparotomy was performed to expose
the abdominal vena cava for drug delivery. Muscle paralysis was
provided by intravenous administration of decamethonium bro-
mide (25 mg/kg). After establishment of a stable airway pressure,
acetylcholine was injected intravenously (50 
 
m
 
g/kg) and dynamic
airway pressure was followed for 5 min. Airway responsiveness
was defined by the time-integrated rise in peak airway pressure
termed the airway-pressure-time index (cm H
 
2
 
O-s).
 
Assessment of Airway Inflammation.
 
After airway responsiveness
measurements, lungs were lavaged three times with one 1.0-ml
aliquot of HBSS (Biofluids, Gaithersburg, MD). The lavage fluid
was centrifuged (1,500 rpm 
 
3
 
 8 min), the supernatant was re-
moved for cytokine analysis, and the cell pellet was resuspended
in normal saline after a brief hypotonic exposure to lyse red blood
cells. Total cells were counted with a hemacytometer. Cytospin
preparations were prepared and stained with Diff-Quik (Baxter,
McGraw Park, IL), and BAL cell differential percentages were
determined based on light microscopic evaluation of 
 
.
 
500 cells/
slide.
 
BAL Cytokine Analysis.
 
Cytokine protein levels were mea-
sured in duplicate samples of unconcentrated BAL fluid (100 
 
m
 
l)
from each animal by ELISA as previously described (8). Assays for
IL-4, IL-5, and IFN-
 
g
 
 were conducted using matched antibody
pairs obtained from PharMingen (San Diego, CA) according to
the manufacturer’s instructions. Optical density readings of sam-
ples were converted to picograms per milliliter using values ob-
tained from standard curves generated with varying concentra-
tions of mouse recombinant IL-4, IL-5, and IFN-
 
g
 
 (5–2,000 pg/
ml). The limit of detection of each assay was 15 pg/ml. 
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OVA-specific Serum IgG1 and IgG2a Analysis.
 
After airway re-
sponsiveness measurements, a kidney was excised and pooled
blood was collected for antibody analysis. Serum was separated by
centrifugation (1,200 
 
g
 
 
 
3
 
 10 min), and stored at 
 
2
 
80
 
8
 
C until an-
alyzed. OVA-specific IgG1 and IgG2a serum antibody levels
were determined by sandwich ELISA in 96-well ELISA plates.
Sample wells were coated with a 0.01% OVA solution in PBS (50
 
m
 
l/well) and incubated at room temperature overnight. Wells
were then blocked with 10% FBS in PBS (200 
 
m
 
l/well) at room
temperature for 2 h. After a wash procedure with 0.05% Tween-
20 in PBS, serum samples were thawed and diluted 1:100, 1:250,
and 1:500 with 10% FBS in PBS. Samples (100 
 
m
 
l/well) were in-
cubated overnight at 4
 
8
 
C. Plates were washed with 0.05%
Tween-20/PBS and incubated with biotin-conjugated anti–
mouse IgG1 (1/2,000; 
 
g
 
l chain specific) or IgG2a (1/2,000; 
 
g
 
2a
chain specific; PharMingen, San Diego, CA; 100 
 
m
 
l/well) at
room temperature for 1 h. After another wash procedure, plates
were incubated for 1 h at room temperature with 100 
 
m
 
l/well of
0.0025 mg/ml avidin peroxidase (Sigma Chemical Co.) in 10%
FBS/PBS. Plates were developed with ABTS (2.2
 
9
 
-azino-did[3-
ethyl-benzthiazone sulfonate]; Kirkegaard & Perry Labs., Inc.,
Gaithersburg, MD; 100 
 
m
 
l/well). Plates were read at 405 nm
within 30 min. Reported OD values are of serum samples diluted
1:250 with 10% FBS/PBS since these values were proven to be
below the saturation point of the assay by comparison of OD val-
ues obtained from serum samples diluted 1:100. There were no
detectable OVA-specific IgG1 antibodies in samples from PBS
control animals.
 
Total Serum IgE Analysis.
 
Sera were obtained from blood
taken during exsanguination of the animals after airway respon-
siveness measurements. An IgE-specific ELISA was used to quan-
titate total IgE Ab levels in serum using complementary antibody
pairs for mouse IgE (R35-72 and R35-92) obtained from
PharMingen according to the manufacturer’s instructions. Dupli-
cate samples (100 
 
m
 
l of a 1/50 dilution in 10% FBS in PBS) were
examined from each animal. OD readings of samples were con-
verted to picograms per milliliter using values obtained from stan-
dard curves generated with varying known concentrations of re-
combinant mouse IgE (5–2,000 pg/ml), and the final
concentration was obtained by multiplying by the dilution factor.
 
Lung Histology.
 
To examine mucus cell content in the airway
wall, lungs were excised after airway measurements and placed
directly in 10% formalin. They were then washed in 70% ethanol,
dehydrated, embedded in glycol methacrylate, cut into 10-
 
m
 
m
sections, mounted on slides, and stained with hematoxylin and
eosin and periodic acid Schiff.
 
Immunohistochemical Detection of VCAM-1.
 
3 d after aspiration
challenge, lungs were excised and placed in periodate-lysine-
paraformaldehyde fixative overnight at 4
 
8
 
C. They were then
soaked in 30% sucrose for 2 d at 4
 
8
 
C and then snap frozen in a
liquid nitrogen cooled isopentane mixture and stored at 
 
2
 
80
 
8
 
C.
Cryostat sections (10 
 
m
 
m) were cut and melted onto coated
slides. Endogenous peroxidase was blocked with 0.1% sodium
azide in 1.0% hydrogen peroxide diluted in PBS. Nonspecific re-
actions were minimized by blocking with CAS-Block (Zymed
Laboratories, South San Francisco, CA) and 2% normal goat se-
rum. Sections were incubated with either rat anti–mouse
VCAM-1 antibodies (M/K-2, rat IgG; Southern Biotechnology
Associates, Inc., Birmingham, AL; 5 mg/ml, 1:1,500) or an iso-
type-matched control antibody (rat IgG; Southern Biotechnology
Associates, Inc.) at the same dilution for 1 h at room temperature.
After a wash procedure, sections were incubated with mouse-
absorbed goat anti–rat IgG antibodies (Southern Biotechnology
 
Associates, Inc.; 0.5 mg/ml, diluted 1:1,500) for 30 min at room
temperature. Positive VCAM-1 staining was detected using the
avidin-biotin-peroxidase complex method (ABC kit; Biogenex,
San Ramon, CA) using 3.3
 
9
 
 diaminobenzidine (DAB substrate
kit; Biogenex, San Ramon, CA).
 
Data Analysis.
 
Data was reported as mean 
 
6 
 
SE. Differences
between means were determined by analysis of variance using
Fisher’s least significant difference test for multiple comparisons.
Significance was assumed at 
 
P
 
 values of 
 
,
 
0.05.
 
Results
 
Antigen-induced AHR Is Mediated by Stat6.
 
To deter-
mine the importance of Stat6 signaling in the development
of allergic responses, measurements of airway reactivity to
intravenous Ach were performed on PBS- and OVA-
treated wild-type and Stat6-deficient mice (Fig. 1). Wild-type
animals sensitized and challenged with OVA developed
significant increases in airway reactivity to Ach compared
to wild-type animals challenged with PBS. In marked con-
trast, OVA-sensitized and challenged Stat6-deficient mice
did not develop a significant increase in airway reactivity
compared to their PBS-treated controls. These results indi-
cate that the development of antigen-induced AHR is
completely dependent upon Stat6 signaling.
 
Stat6 Partially Mediates the Development of Pulmonary Eosin-
ophilia.
 
To examine the role of Stat6 signaling in antigen-
induced pulmonary inflammation, we examined the cell
profile of bronchoalveolar lavage fluids obtained from
Stat6-deficient and wild-type BALB/c mice. OVA sensiti-
zation and challenge induced equivalent increases in BAL
macrophages and lymphocytes in OVA-treated wild-type
and Stat6-deficient animals (Fig. 2). Striking increases were
observed in the number of eosinophils recovered in the la-
vage fluid of OVA-treated wild-type mice as compared to
their PBS controls (
 
P
 
 
 
,
 
0.05). Although increases in BAL
eosinophils were also observed in OVA-treated Stat6-defi-
cient mice, they were 
 
z
 
50% of that found in OVA-treated
wild-type animals. These results suggest that antigen-induced
pulmonary eosinophilia is only partially dependent on Stat6
signaling pathways.
 
Allergen-induced Increases in BAL IL-4 and IL-5 Cytokine
Levels Are Mediated by Stat6.
 
Since previous studies have
shown that Stat6 signaling is important in T helper cell de-
velopment (22–24), we examined the role of Stat6 in cy-
tokine production in the lung after antigen provocation.
Figure 1. Effects of Stat6 gene
disruption on airway reactivity to
intravenous acetylcholine (50
mg/kg) in mice 3 d after a single
aspiration challenge with anti-
gen (1.5% OVA) or PBS. Values
shown are mean and SE (n 5 9).
* P value ,0.05 versus all other
groups; 1 P value ,0.05 versus
Ag-treated Stat6-deficient group.
APTI, airway-pressure-time in-
dex, cm H2O-sec. 
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IL-4, IL-5, and IFN-
 
g
 
 proteins were detected at low levels
in the BAL fluids of both PBS-exposed wild-type and
Stat6-deficient animals. Antigen challenge of OVA-treated
wild-type animals resulted in significant increases in BAL
protein levels of the Th2 cytokines, IL-4 and IL-5, com-
pared to their PBS-treated controls. In contrast, antigen
challenge of Stat6-deficient mice did not result in eleva-
tions in either IL-4 or IL-5 levels as compared to their
PBS-treated controls (Fig. 3, 
 
A
 
 and 
 
B
 
). Antigen exposure
did result in significant increases in IFN-
 
g
 
 levels in both
wild-type and Stat6-deficient mice; however, no differ-
ences were noted between these groups (Fig. 3 
 
C
 
). These
results indicate that Stat6 signaling is essential for the devel-
opment of a type 2 cytokine pattern in the lung after pul-
monary antigen exposure.
 
Stat6 Signaling Is Essential for IgE Production.
 
Since IgE
is thought to be important in the pathogenesis of allergic
responses (25), we measured the total IgE levels in OVA-
treated wild-type and Stat6-deficient animals. OVA-treated
wild-type animals produced significantly more IgE than
that produced by their PBS-treated littermates. Strikingly,
neither PBS- nor OVA-treated Stat6-deficient animals
produced detectable levels of serum IgE (Fig. 4). This find-
ing indicates that both basal and antigen-induced IgE pro-
duction is completely dependent on Stat6 signaling.
 
Differential Expression of Specific IgG1 and IgG2a Ab in
OVA-treated Wild-type and Stat6-deficient Animals.
 
We ex-
amined serum levels of OVA-specific IgG1 and IgG2a Abs
after OVA challenge. This method has been used previ-
ously to assess the relative influence of Th1 versus Th2 cy-
tokines in vivo, since the production of the mouse 
 
g
 
l sub-
class is augmented by IL-4 and inhibited by IFN-
 
g
 
,
whereas that of 
 
g
 
2 is augmented by IFN-
 
g
 
 and inhibited
by IL-4 (26). In wild-type mice exposed to OVA, signifi-
cant levels of both IgG1 and IgG2a are observed; however,
IgG1 levels were predominant (Fig. 5, 
 
A
 
 and 
 
B
 
). In con-
trast, the levels of OVA-specific IgG1 were significantly
lower in Stat6-deficient animals than in wild type, whereas
their OVA-specific IgG2a levels were significantly higher.
Figure 2. Effects of Stat6 gene disruption on the numbers of BAL in-
flammatory cells recovered from mice 3 d after a single antigen or PBS as-
piration challenge. Mice were treated as described in Fig. 1. Values shown
are mean and SE (n 5 9). * P value ,0.05 versus PBS-treated groups.
Figure 3. Effect of Stat6 deficiency on IL-4 (A), IL-5 (B), and IFN-g
(C) protein levels in BAL fluids of mice 3 d after a single antigen or PBS
aspiration challenge. Mice were treated as described in Fig. 1. Protein lev-
els were analyzed by ELISA. OD readings were converted to picograms
per milliliter by comparison with standard curves. Values shown are mean
and SE (n 5 9). * P value ,0.05 versus PBS-treated groups; 1 P value
,0.05 versus Ag-treated Stat6-deficient group.
Figure 4. Effect of Stat6 gene
disruption on serum total IgE
levels of mice 3 d after a single
antigen or PBS aspiration chal-
lenge. Mice were treated as de-
scribed in Fig. 1. Serum was di-
luted 1:50 for total IgE and
analyzed by ELISA. OD readings
were converted to nanograms
per milliliter by comparison with
a standard curve. Values are reported as mean and SE (n 5 9). * P value
,0.05 versus PBS-treated groups; 1 P value ,0.05 versus Ag-treated
Stat6-deficient animals.
Figure 5. Effect of Stat6 defi-
ciency on serum OVA-specific
IgG1 (A) and OVA-specific
IgG2a (B) antibody levels of
mice 3 d after a single antigen or
PBS aspiration challenge. Mice
were treated as described in Fig.
1. Serum was diluted 1:100, 1:
250, and 1:500 with FBS for
analysis of OVA-specific IgG1
and IgG2a antibody levels by
ELISA. Since recombinant
OVA-specific antibodies were not available to generate a standard curve,
relative antibody levels are reported using OD readings obtained after
background absorbance was subtracted. Reported OD values are from
samples diluted 1:250, all of which were below the saturation point of the
assay as demonstrated by comparison to OD values obtained from samples
diluted 1:100. Values are reported as mean and SE (n 5 9). * P value
,0.05 versus PBS-treated groups; 1 P value ,0.05 versus OVA-treated
Stat6-deficient animals.943 Kuperman et al.
Figure 6. Effects of Stat6 gene disruption on antigen-induced increases in the number of mucus-containing cells in the airway epithelium. Lung sec-
tions (n 5 4/experimental group, four sections per animal) from OVA-treated wild-type (A) and Stat6-deficient (B) mice were stained with periodic acid
Schiff. (A) Lung section of antigen-treated wild-type mouse demonstrating interstitial inflammatory cells and a large degree of goblet cell hyperplasia. (B)
Lung section of antigen-treated Stat6-deficient mouse demonstrating interstitial inflammatory cells and an absence of mucus-containing cells. Bars, 100 mm.
Figure 7. Immunohistochemical detection of VCAM-1 expression in lung sections from antigen-treated wild-type and Stat6-deficient mice treated as
described in Fig. 1 legend. Lung sections (n 5 2, four sections per animal) from either antigen-treated wild-type (A and B) or Stat6-deficient animals (C
and D) were incubated with either isotype-matched control IgG mAb (A and C) or anti–VCAM-1 mAb (B and D). Notice comparable VCAM-1–posi-
tive staining in sections from antigen-treated wild-type and Stat6-deficient mice (B and D). Notice lack of positive staining in sections incubated with the
isotype-matched control antibody (A and C). Bars, 50 mm.944 Stat6 Signaling in Allergic Airway Responses
As expected, the levels of OVA-specific Ab isotypes in
PBS-sensitized and challenged mice of both wild type and
Stat6 deficiency were below the level of detection. These
results are consistent with a lack of Th2 cytokine produc-
tion in antigen-treated Stat6-deficient animals.
Stat6 Signaling Is Essential for Airway Goblet Cell Differenti-
ation. As we (9) and others (27, 28) have previously dem-
onstrated that IL-4 is important in regulating mucus pro-
duction in the airways, we examined the potential role of
Stat6 signaling in this process. We find that many cells in
the epithelial layer of the airway wall stain positive for mu-
cus after antigen challenge of wild-type mice. In marked
contrast, Stat6 deficiency completely prevented the in-
crease in mucus containing cells in the airway epithelium of
antigen-exposed mice (Fig. 6, A and B). This finding is sig-
nificant in that airway mucus hypersecretion is a common
feature of allergic asthma and has been found to be particu-
larly profound in autopsy examination of lungs from pa-
tients who have died in status asthmaticus.
Stat6 Signaling Does Not Mediate Lung Endothelial Cell
VCAM-1 Expression. As Stat6 appears to only partially
mediate antigen-induced pulmonary eosinophilia, we
sought to determine whether the Stat6-dependent eosino-
philia was due to induction of VCAM-1 expression. We
examined VCAM-1 immunoreactivity in lung sections
from OVA-treated Stat6-deficient and wild-type animals.
Our results suggest that lung endothelial cells stain positive
for VCAM-1 in sections taken from both OVA-treated
wild-type and Stat6-deficient animals (Fig. 7, B and D).
Lung sections treated with the secondary antibody only,
showed no staining, indicating that the protocol used re-
sulted only in specific staining for VCAM-1. These results
indicate that Stat6 does not mediate VCAM-1 expression
on lung endothelial cells after allergen challenge.
Discussion
In this study, we demonstrate that Stat6 signaling is es-
sential for the development of allergen-induced AHR since
Stat6-deficient animals do not develop hyperresponsiveness
in response to an antigen exposure regime that induces
AHR in their wild-type littermates. In addition, antigen-
induced mucus cell hypertrophy was completely dependent
on Stat6 signaling. Interestingly, allergen-induced pulmo-
nary eosinophilia was only partially dependent on Stat6 sig-
naling. The Stat6-dependent eosinophilia did not appear to
be mediated via VCAM-1 upregulation since positive
staining of VCAM-1 was observed in lungs from both
OVA-treated wild-type and Stat6-deficient animals. These
results provide the first in vivo evidence that Stat6 signaling
is required for the development of Th2-mediated allergic
airway responses to inhaled antigens.
As Th2 cytokines have been hypothesized to mediate al-
lergen-induced allergic airway responses (1–3, 8) and Stat6
proteins have been shown to be essential in Th2 differenti-
ation in vitro (22–24), we examined the role of this tran-
scription factor in cytokine production in the lung after an-
tigen provocation. Our results demonstrate that Stat6
signaling is essential for antigen-induced increases in Th2
cytokine production in vivo. Antigen challenge of wild-
type animals resulted in significant elevations in the type 2
cytokines (i.e., IL-4 and IL-5) in the bronchoalveolar lav-
age fluids of wild-type animals. In marked contrast, Stat6-
deficient animals were unable to produce IL-4 or IL-5 in
response to local antigen provocation. The lack of Th2 cy-
tokine production after antigen challenge in Stat6-deficient
animals was also reflected in the balance of Th1- and Th2-
dependent antibody isotype production in the serum of wild-
type and Stat6-deficient animals. OVA-treated wild-type
animals developed a predominant IgG1 and IgE antibody
profile with lower IgG2a levels. In contrast, Stat6-deficient
animals have predominant IgG2a antibody production and
virtually no detectable IgE. These results are consistent
with previous reports of the inability of lymphocytes from
Stat6-deficient mice to differentiate into Th2s when stimu-
lated in vitro under conditions that favor the generation of
Th2s. Despite the lack of antigen-induced increases in IL-4
production in Stat6-deficient animals, low levels of IL-4
and IL-5 were observed in PBS-treated Stat6-deficient ani-
mals, perhaps suggesting that these cytokines may be pro-
duced by non–T cells independent of Stat6 pathways. In-
terestingly, Th1 cytokine production was not impaired in
Stat6-deficient animals as antigen-induced increases in
IFN-g were equivalent in wild-type and Stat6-deficient
animals. Thus, this study provides in vivo evidence for the
essential role of Stat6 in mediating the differentiation sig-
nals induced by either IL-4 or IL-13 after allergen provoca-
tion.
This study reveals that Stat6 is essential for the develop-
ment of allergen-induced AHR as Stat6-deficient animals
did not become hyperresponsive after antigen sensitization
and challenge, as did their wild-type littermates. The lack
of antigen-induced AHR in Stat6-deficient animals was as-
sociated with the inability of these animals to produce Th2
cytokines in response to antigen challenge. The association
of antigen-induced AHR with increased Th2 type cyto-
kine expression is consistent with our previous demonstra-
tion that these functional responses are dependent on
CD41 T cells (7) and associated with the production of
type 2 cytokines (8).
One of the characteristics of allergic asthma is the pres-
ence of elevated serum IgE levels. IL-4 has clearly been
shown to be a key regulator of the synthesis of IgE (6). In
addition, IL-4 in conjunction with IL-3 acts as a mast cell
growth factor (14). Together, these actions of IL-4 may
promote IgE-Fc receptor–mediated mast cell degranula-
tion. Upon degranulation, mast cells release a variety of
bronchoconstrictor mediators, including histamine and leu-
kotrienes, that may contribute to the development of
AHR. In addition, activated mast cells can secrete IL-4, IL-5,
and platelet activating factor (PAF) that may further am-
plify inflammatory processes (29, 30). The results of our
study support a role for IgE-dependent processes in AHR
in that after allergen sensitization and challenge Stat6-defi-
cient animals do not have increased IgE levels or AHR.
However, several recent studies in mice deficient in either945 Kuperman et al.
B cells (31) or IgE (32) have shown that allergen-induced
AHR develops in the absence of IgE-mediated mast cell
activation. Although our study clearly demonstrates that
Stat6 signaling is essential for IgE production after allergen
exposure, further studies are necessary to determine the exact
role of IgE-dependent processes in the pathogenesis of AHR.
Eosinophilic inflammation is clearly a hallmark of allergic
asthma and considerable evidence suggests an association
between pulmonary eosinophil infiltration and AHR in
human asthma (33). Eosinophils are postulated to induce
AHR through release of several cationic proteins, eosino-
philic cationic protein (ECP), and major basic protein
(MBP), which are thought to damage the airway epithe-
lium leaving smooth muscle more susceptible to contractile
mechanisms (34). Although IL-5 has clearly been shown to
be important in promoting the activation (35) and survival
(36) of eosinophils in tissues, IL-4 may also contribute to
eosinophilia by promoting IL-5 production and the upreg-
ulation of endothelial VCAM-1 expression that controls
the attachment and migration of eosinophils. In previous
studies, it has been difficult to dissociate direct effects of IL-4
on eosinophil recruitment from its role in expansion of
Th2s and subsequent increases in IL-5 production. This
study suggests that multiple mechanisms are likely to con-
tribute to antigen-induced tissue eosinophilia since Stat6
gene disruption only partially suppresses antigen-induced
increases in BAL eosinophils. Thus, we conclude that there
are both Stat6-dependent and -independent mechanisms of
antigen-induced eosinophilia. The Stat6-dependent mech-
anism of eosinophilia is likely due to Stat6’s role in induc-
tion of Th2 differentiation as the increases in BAL eosino-
phils in wild-type animals were correlated with increases in
IL-5 levels. The reduction in eosinophils in the BAL of
Stat6-deficient mice, as compared to their littermates, was
likely due to the lack of Th2 differentiation and IL-5 pro-
duction in these animals. The Stat6-independent mecha-
nism(s) are not likely to be IL-5 mediated as antigen chal-
lenge of Stat6-deficient animals resulted in significant
increases in eosinophils in the BAL without concomitant
increases in IL-5 protein levels. These results suggest that
the Stat6-independent eosinophilia is due to either IL-4–con-
trolled processes mediated by intracellular signaling path-
ways besides Stat6 or to IL-4–independent processes such
as the production of eotaxin and monocyte chemoattrac-
tant protein 5, which have recently been shown to play a
role in lung eosinophilia.
Based on previous reports that IL-4 contributes to tissue
eosinophilia via upregulation of VCAM-1 (13) and that IL-4
induction of VCAM-1 expression on endothelial cells may
be Stat6 mediated (37), we sought to determine whether
the Stat6-dependent eosinophilia observed in our study was
mediated via induction of VCAM-1 expression on vascular
endothelial cells. We examined VCAM-1 expression in
lung sections from OVA-treated Stat6-deficient and wild-
type animals. Surprisingly, we found that VCAM-1 staining
is evident in both wild-type and Stat6-deficient animals,
suggesting that Stat6 is not essential for VCAM-1 expression.
However, as we did not quantitate the level of VCAM-1
staining, we cannot rule out some degree of Stat6 involve-
ment. These findings suggest that antigen-induced VCAM-1
expression is not mediated via IL-4–induced activation of
Stat6, but may be due to either other IL-4–dependent sig-
naling pathways besides Stat6 or entirely IL-4 independent.
Consistent with the hypothesis that VCAM-1 expression
may not be entirely IL-4 dependent, Najakima et al. (38)
has previously demonstrated that anti–IL-4 mAb adminis-
tration to antigen-challenged mice only partially blocked
VCAM-1 expression.
Stat6 deficiency resulted in the complete prevention of
antigen-induced AHR, even in the presence of eosino-
philic inflammation, albeit attenuated, indicating that the
development of antigen-induced AHR in this model is not
mediated directly by eosinophils. As we did not evaluate
the activation state of eosinophils in this study, one might
argue that the eosinophils in Stat6-deficient animals may
not have been activated. However, several other studies in
murine models support our conclusion that airway eosino-
philia and AHR are separable events (16, 39). For instance,
Corry et al. (16) demonstrated that anti–IL-5 antibody ad-
ministration to OVA-sensitized mice at levels that sup-
pressed eosinophils had no effect on subsequent antigen-
induced airway reactivity. Furthermore, Van Oosterhout et
al. (39) demonstrated that administration of IL-5–produc-
ing cells into the peritoneal cavity of guinea pigs produced
AHR several days before any evidence of eosinophil airway
recruitment. Lastly, naive IL-4 transgenic mice that have a
profound pulmonary eosinophilia are not hyperresponsive
to cholinergic stimulation (27). On the other hand, studies
of IL-5–deficient mice support a role for IL-5 and eosino-
phils in the development of allergen-induced AHR (40). A
potential explanation for these discrepancies may be pro-
vided by Kraneveld et al. (41) who demonstrate that IL-5 is
indeed important in AHR, but perhaps not via recruitment
of eosinophilia alone but through release of neuropeptides
capable of inducing bronchoconstriction and AHR to con-
tractile agents. Our results would support this conclusion in
that when levels of IL-5 were low in Stat6-deficient mice,
no AHR occurred despite the presence of eosinophils. Fur-
ther studies are clearly necessary to define the exact role of
eosinophils in allergen-induced AHR.
Our results indicate that Stat6 signaling is essential in an-
tigen-induced mucus production as mucus containing cells
were not evident in the lungs of antigen-challenged Stat6-
deficient mice. This finding is consistent with our previous
demonstration that blockade of the IL-4 receptor pre-
vented antigen-induced increases in mucus-containing cells
(9) and with the findings of Rankin et al. (27) who demon-
strated that naive IL-4 transgenic mice had profound in-
creases in mucus-containing cells in the airway epithelium.
As the mucus cell hyperplasia in both of these studies was
associated with the presence of eosinophils in the airways,
the precise effects of IL-4 could not be separated from
those of other inflammatory cells found in the lung. How-
ever, in this study, no mucus-containing cells were present
in the lungs of allergen-exposed Stat6-deficient animals,
despite the presence of eosinophils, suggesting that the dif-946 Stat6 Signaling in Allergic Airway Responses
ferentiation of airway epithelial cells to mucus-containing
cells is likely a result of direct IL-4 stimulation. This hy-
pothesis is consistent with a recent study demonstrating that
IL-4 induces expression of a specific mucin gene, MUC5AC,
in the airways of IL-4 transgenic mice (28). Taken to-
gether, these studies strongly support a pivotal role for IL-4
or IL-13 and Stat6 activation in mucus hypersecretion and
plugging in the airways, which is characteristic of patients
who die from asthma (42), cystic fibrosis (43), and chronic
bronchitis (43).
Although many of the processes examined in this study
are clearly IL-4 dependent, Stat6 has also been shown to be
activated in response to IL-13 and platelet-derived growth
factor (PDGF) receptor stimulation (44). IL-13 is another
pleiotropic regulatory cytokine that shares a number of bi-
ological properties with IL-4, such as the differentiation of
Th2s (22), the induction of VCAM-1 in cultured human
endothelial cells (37), and stimulation of B cell class switch-
ing to IgE production. Although IL-13 levels have been
shown to be elevated in the BAL cells of asthmatics (45),
no direct determination of its role in the pathogenesis of al-
lergic asthma has been conducted. PDGF is thought to be
important in tissue repair processes and is a potent activat-
ing factor for mesenchymal cells including fibroblasts and
smooth muscle cells. A thickened basement membrane due
to increased collagen deposition and hypertrophy of airway
smooth muscle cells is a common feature of asthmatic air-
ways upon biopsy. However, two separate studies have
shown no correlation between either PDGF levels in BAL
or PDGF receptor expression in lung biopsies and asthma
(46, 47).
In summary, our results demonstrate that Stat6 is essen-
tial in the development of allergen-induced AHR. Stat6
likely mediates AHR via its pivotal role in Th2 differentia-
tion resulting in subsequent stimulation of IgE synthesis
and mucus production in the airways. Conversely, our
studies indicate that Stat6 only partially mediates antigen-
induced eosinophilia, and that eosinophils are not required
for the development of allergen-induced AHR in this
model. Furthermore, although VCAM-1 expression on the
pulmonary vasculature may contribute to eosinophil re-
cruitment, it is not mediated via IL-4– or IL-13–activated
Stat6 pathways as previously hypothesized. We conclude
that interrupting Stat6 signaling provides a very effective
means of preventing many of the symptoms that are com-
mon to allergic asthma. Drugs designed to block Stat6 acti-
vation may provide a specific and effective means of com-
bating the multiple symptoms of allergic asthma without the
toxic side effects of steroid treatments that are now com-
monly in use.
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